UBT251 Phase II Data Intensify Triple-Agonist Competition in Diabetes

New phase 2 data reported on March 25, 2026 by Novo Nordisk and China-based The United Laboratories International Holdings Limited (TUL) for a next-generation triple agonist Indicate intensifying competition in the rapidly evolving glucagon-like peptide-1 (GLP-1) and incretin-based therapy landscape.¹ Multi-target approaches are emerging as a key strategy to differentiate efficacy across diabetes and obesity markets in this therapy landscape.

The companies announced topline results showing that UBT251, a GLP-1/glucose-dependent insulinotropic polypeptide (GIP)/glucagon (triple-G) receptor agonist, achieved substantial glycemic and weight reductions in patients with type 2 diabetes, reinforcing momentum toward more potent, multi-mechanism metabolic therapies.¹

“Following the recent positive read-out of phase 2 data in people with overweight or obesity, we are encouraged to see the results of this trial, which also demonstrate the potential of UBT251 in a type 2 diabetes population,” said Martin Holst Lange, MD, PhD, executive vice president, chief scientific officer, and head of Research and Development at Novo Nordisk, in a company press release.¹ “Novo Nordisk will initiate a global phase 2 trial with UBT251 in people with type 2 diabetes later this year, and we are already conducting a global phase 2 trial in weight management that will read out next year.”

What were the study results?

In the randomized, double-blind phase 2 trial conducted in China, once-weekly administration of UBT251 (2 mg, 4 mg and 6 mg doses) demonstrated a mean glycated hemoglobin (HbA1c) reduction of up to 2.16% from a baseline of 8.12% after 24 weeks, compared with a 1.77% reduction for semaglutide (1 mg) and 0.66% for placebo. The therapy also showed a mean body weight reduction of up to 9.8%, compared to 4.8% with semaglutide and 1.4% with placebo, based on a baseline weight of 80.1 kg (approximately 177 lbs).

These findings place UBT251 among a growing class of triple agonists aiming to surpass established GLP-1-based therapies by simultaneously targeting multiple metabolic pathways. Recent industry developments have highlighted increasing competitive pressure within the GLP-1 space, with biopharma companies advancing dual- and triple-agonist candidates designed to improve glycemic control, weight loss, and cardiometabolic outcomes beyond current standards.²

How does UBT251 compare to existing GLP-1 therapies in efficacy and weight loss?

In addition to primary glycemic endpoints, UBT251 demonstrated improvements across multiple secondary measures, including waist circumference, blood pressure, and lipid profiles. The magnitude of HbA1c and weight reduction observed in the study exceeded that of semaglutide 1 mg, suggesting potential differentiation in both metabolic control and weight management, which are 2 critical endpoints shaping competition in this therapeutic class.

What is the development and regulatory path forward for UBT251?

Based on the phase 2 findings, The United Bio-Technology (Hengqin), a wholly owned subsidiary of TUL, plans to initiate two phase 3 trials in Chinese patients with type 2 diabetes. Novo Nordisk, which holds global development and commercialization rights outside Greater China under a March 2025 agreement,³ expects to initiate a global phase 2 trial in the second half of 2026.

UBT251 is also being evaluated in a separate global phase 1b/2a study in overweight or obese individuals, with topline results anticipated in 2027, according to the companies. Together, these programs reflect a dual-indication strategy targeting both diabetes and obesity, aligning with broader industry trends toward integrated metabolic disease management.

As competition intensifies across the incretin landscape, particularly with next-generation candidates advancing through mid- and late-stage pipelines, the ability to demonstrate superior efficacy across both glycemic control and weight reduction may define future standards of care and market leadership.

References

1. Novo Nordisk. Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes. Published March 25, 2026. Accessed March 25, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916519
2. Wen J, Nadora D, Truong A, et al. Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review. Nutr., Metab. Cardiovasc. Dis. 2005;35(12):104213. doi: 10.1016/j.numecd.2025.104213
3. Novo Nordisk. The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist. Published March 24, 2025. Accessed March 25, 2026. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915958